Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.50 |
| ▸ | DRD2 | P14416 | 10/20 | 0.50 |
| ▸ | HTR2A | P28223 | 10/20 | 0.50 |
| ▸ | HTR7 | P34969 | 10/20 | 0.50 |
| ▸ | HTR6 | P50406 | 10/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30784981 | 0.98 | HTR1A (0.51) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL2452980 | 0.86 | TLR8 (0.41) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL30784994 | 0.84 | HTR1A (0.52) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL30740023 | 0.81 | HTT (0.56) | KDM4EMEN1LMNAKMT2A | |
| SCHEMBL30785003 | 0.81 | MEN1 (0.52) | MEN1LMNAKMT2A | |
| SCHEMBL1308939 | 0.79 | LMNA (0.51) | PIM1LMNA | |
| SCHEMBL8413067 | 0.76 | HTR2B (0.52) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL13406345 | 0.76 | SIGMAR1 (0.45) | PIM1MEN1LMNAKMT2A | |
| SCHEMBL8468231 | 0.75 | PIM1 (0.47) | PIM1MEN1KMT2A | |
| SCHEMBL30784986 | 0.75 | HTR1A (0.60) | HTR1ADRD2HTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | HTR1A 3602/4885DRD2 4772/4885HTR2A 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.